SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

BELLUS Health Inc. (BLUSF)

BLUSF RSS Feed
Add BLUSF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 6/20/2016 10:05:29 PM - Followers: 5 - Board type: Free - Posts Today: 0



Ticker : (BLU.TO)  (BLUSF)

Market Cap : $20.86 Million
Cash : $16
.3 M
Burn-Rate : $900K per Quarter


Shares Outstanding : 47.7 Million ( 70% of these Shares held by Insiders and Institutions)
Low Float : 20 Million






New Presentation January 2014
http://www.bellushealth.com/files/doc_presentations/Bellus%20Corporate%20Presentation%20January%202014%20vFINAL.pdf


Ceo Interview November 2013
http://watch.bnn.ca/#clip1047918



Another Interview from Mid 2013
http://www.pharmaboardroom.com/article/interview-roberto-bellini-president-ceo-bellus-health-canada



Insider Activity
http://canadianinsider.com/node/7?menu_tickersearch=blu

BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.

The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).

In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.

BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, which is a rare disease where proteins build up in various parts of the body, mainly in the kidneys, heart, liver and peripheral nerves.

The Company is also seeking other products opportunities that show potential for development.

BELLUS Health trades on the Toronto Stock Exchange under the ticker BLU.

- See more at: http://www.bellushealth.com/English/investors/investors-overview/default.aspx#sthash.udfjq99M.dpuf

BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.

The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).

In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.

BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, which is a rare disease where proteins build up in various parts of the body, mainly in the kidneys, heart, liver and peripheral nerves.

The Company is also seeking other products opportunities that show potential for development.

BELLUS Health trades on the Toronto Stock Exchange under the ticker BLU.

- See more at: http://www.bellushealth.com/English/investors/investors-overview/default.aspx#sthash.udfjq99M.dpuf



BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.

The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).

In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.

BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, which is a rare disease where proteins build up in various parts of the body, mainly in the kidneys, heart, liver and peripheral nerves.

The Company is also seeking other products opportunities that show potential for development.

BELLUS Health trades on the Toronto Stock Exchange under the ticker BLU.

- See more at: http://www.bellushealth.com/English/investors/investors-overview/default.aspx#sthash.udfjq99M.dpuf

BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.

The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).

In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.


Some key reasons to consider investing in BELLUS Health include:

Focus on rare diseases – pipeline of rare disease projects in areas of high unmet medical need

Late stage pipeline – global Phase III study for KIACTA™ currently enrolling patients

Fully funded business plan – strong balance sheet with cash runway that will meet funding requirements beyond 2017

Key shareholders –shareholder base with proven track record of building successful healthcare companies













  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLUSF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#252   Let's hope everyone who wanted out is now out. ErnieBilco 06/20/16 10:05:29 PM
#251   Getting thumped today. willlbone 06/20/16 09:47:49 AM
#250   today announced the completion of the KIACTA™ (eprodisate) xr_biotech_consult 01/21/16 08:36:40 AM
#249   Great article !! gnt77 09/06/14 11:23:24 AM
#248   I agree. I have a feeling they are gnt77 06/27/14 07:56:29 PM
#247   Where is everyone?........This is a 10 bagger in joelvol 06/18/14 07:22:36 PM
#246   What? You couldn't wait another day for me? SmurfVA 02/27/14 03:54:15 PM
#245   Where are we with this? Key here SmurfVA 02/25/14 12:09:05 PM
#244   Most definitely fam401! SmurfVA 01/30/14 08:39:07 AM
#243   I'm guessing we will get a nice boost fam401 01/30/14 01:07:33 AM
#242   Key here is Enrollment is expected to be SmurfVA 01/30/14 01:00:56 AM
#241   The Phase III Confirmatory Study is designed to SmurfVA 01/30/14 12:57:18 AM
#240   Do you expect a steady run up until then? fam401 01/30/14 12:34:06 AM
#239   ~ thank you Bio Specialist! kei 01/29/14 09:51:26 PM
#238   kei 01/29/14 09:50:30 PM
#237   full phase 3 results will be out in BioSpecialist 01/29/14 05:30:00 PM
#236   question to the board: when will their p3 kei 01/29/14 04:29:14 PM
#232   Thank you for your opinion! Greatly appreciated! fam401 01/28/14 05:25:34 PM
#231   From scrapped info out on the web. SmurfVA 01/28/14 05:06:20 PM
#230   What's your out look on 2014 for this fam401 01/28/14 05:00:14 PM
#229   Looking to get in on some BLUSF here SmurfVA 01/28/14 04:55:58 PM
#228   What's the potential target on this one? fam401 01/28/14 02:47:51 PM
#227   BLUSF-DD ..A FANTASTIC INVESTMENT TO MAKE BIG MONEY !!! BioSpecialist 01/28/14 09:29:38 AM
#226   Yea it's looking good for 2011 IMO mod KrakenTaken 12/28/10 07:50:01 PM
#225   You like AVOP? The Maestro 12/28/10 07:31:56 PM
#224   hey add me as a mod on AVOP KrakenTaken 12/28/10 03:59:25 PM
#223   add me as assistant mod on AVOP please KrakenTaken 12/27/10 12:37:53 PM
#222   Volume stays like this and I may add some. The Maestro 12/20/10 09:35:27 PM
#221   Blus + Volume = Plus The Maestro 12/20/10 09:34:09 PM
#220   $207,000 in volume today. The Maestro 12/20/10 09:30:55 PM
#219   Volume picking up. The Maestro 12/20/10 09:29:26 PM
#218   Looks like there may be some life here. moosegringo 12/17/10 03:25:00 PM
#217   Sell Bellus Health Shares to $1 surf1944 05/07/08 04:59:46 PM
#216   BELLUS HEALTH reports results for first quarter of surf1944 05/05/08 07:14:55 PM
#215   Neurochem to Change Name and Ticker; Stock Up surf1944 04/16/08 08:00:16 AM
#214   At Annual and Special Meeting of Shareholders - surf1944 04/15/08 09:12:54 AM
#213   Following the Drugmaker Formerly Known as Neurochem: surf1944 04/02/08 11:51:07 AM
#212   Neurochem moves eprodisate (KIACTA(TM)) drug development program forward surf1944 03/13/08 10:09:52 AM
#211   Bought back into NRMX, too many shorts still surf1944 02/21/08 11:23:24 AM
#210   Neurochem reports results for fourth quarter and fiscal surf1944 02/21/08 07:16:45 AM
#209   Ticking higher again. screamingeagle 02/12/08 10:23:35 PM
#208   It has come down . Could be screamingeagle 02/09/08 01:44:20 PM
#207   i ve been wathching since 1.55...still up now...good lstedr_adv 02/05/08 11:06:40 AM
#206   Neurochem Faces Kiacta Hurdle in Europe surf1944 12/14/07 09:19:13 AM
#205   Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for surf1944 12/14/07 08:26:51 AM
#204   Canada Hot Stocks To Watch: MPX.UN.T MBT.T NRMX Minddoc7 12/07/07 09:31:00 AM
#203   Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete surf1944 12/06/07 05:45:04 PM
#202   We have some late news. Minddoc7 12/06/07 05:43:12 PM
#201   Look at all the markets. They are also Minddoc7 11/19/07 11:02:56 PM
#200   Ouch!!11% sell off...down we go.. BYUINSDER 11/19/07 05:40:45 PM
PostSubject